Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01651039 · OUTCOME

Clinical Benefit Rate

Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM) · Source last updated 2018-04-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
up to 4 years

What was measured

The number of response rates in participants that have achieved MR, PR, VGPR, CR

Groups in this outcome

Panobinostat, Lenalidomide and Dexamethasone

All patients received oral panobinostat, lenalidomide and dexamethasone as per protocol

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Panobinostat, Lenalidomide and Dexamethasone27

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Panobinostat, Lenalidomide and Dexamethasone20Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        20
denoms
  1. counts
    1. group Id
      OG000
      value
      27
    units
    Participants
description
The number of response rates in participants that have achieved MR, PR, VGPR, CR
groups
  1. description
    All patients received oral panobinostat, lenalidomide and dexamethasone as per protocol
    id
    OG000
    title
    Panobinostat, Lenalidomide and Dexamethasone
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
up to 4 years
title
Clinical Benefit Rate
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice